Chongqing Pharscin Pharmaceutical Co., Ltd. Class A
SSZSE:00290713.68
CNY
+0.21
(+1.56%)
ISIN
CNE100003308
Return %
Stock
S&P 500
1Y
-19.01
13.14
3Y
-14.23
80.78
5Y
17.42
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Hong Tao You
- Full Time Employees
- 1,439
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 89, Middle Sec of Huangshan Ave Chongqing CH China 401120
- IPO Date
- Oct 20, 2017
- Website
- pharscin.com
- Similar Companies
- Business
- Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals, focusing on treatments for central nervous system disorders, digestive diseases, otolaryngology conditions, oncology, cardiovascular and cerebrovascular ailments; it offers tablets including tangerine ice plum tablets, Weidimei magnesium aluminum carbonate chewable tablets and cilostazol tablets; powders, granules such as Bawei Qilong granules; hard and soft capsules including Liuwei Anshen capsules, Duliang softgels, cholesterol softgels and orlistat capsules; powder injections, freeze-dried powder injections; small-volume injections such as injectable gabelate mesylate, omeprazole sodium, sodium ferulinate and troxerutin injections; active pharmaceutical ingredients through synthesis; and botanical drug extractions incorporating traditional Chinese medicine technologies. Founded in 1996 and headquartered in Rongchang District, Chongqing, the company operates 11 to 22 advanced production lines compliant with GMP standards, including automated intelligent systems for extraction of thermosensitive active ingredients, powder transmission and soft capsule production; it maintains a marketing network covering 31 provinces in China with products reaching over 4000 hospitals and is expanding internationally. Subsidiaries include Chongqing Pharscin Medicine Co., Ltd. for pharmaceutical distribution, Chongqing Pharscin Pharmacy Retail Chain Co., Ltd. for retail and Chongqing Pharscin Biotech Co., Ltd. for biotechnology research, supporting an integrated model across pharmaceutical industry, commerce and retail segments. The company holds 68 drug varieties with 49 in China's National Medical Insurance catalog and 46 domestic patents, having undertaken 98 national and provincial R&D projects including "Eleventh Five-Year" and "Twelfth Five-Year" Major New Drug developments; it pursues first-in-class innovative drugs via platforms for cancer driver gene screening, medicinal chemistry and drug metabolism pharmacokinetics. Recent developments encompass expansion of its distribution network through partnerships with over 200 new regional distributors since 2021; completion of shareholding reductions by controlling shareholders and senior management in 2025; updates to drug production licenses and successful GMP compliance checks; industrial and commercial registration changes for holding subsidiaries; and advancements in 5G-enabled intelligent manufacturing as a national high-tech enterprise.